UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): November 13, 2006
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
001-15281
(Commission File Number)
|
|
76-0233274
(I.R.S. Employer Identification No.) |
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 2.02 Results of Operations and Financial Condition
The information in this Item 2.02 of this Current Report is being furnished pursuant to Item
2.02 of Form 8-K and according to general instruction B.2. thereunder, the information in this Item
2.02 of this Current Report shall not be deemed “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The
information in this Item 2.02 of this Current Report shall not be incorporated by reference into
any registration statement pursuant to the Securities Act of 1933.
On November 13, 2006, Repros Therapeutics Inc., a Delaware corporation (the “Company”),
announced the results of its operations for the three months and nine months ended September 30,
2006 and provided an update on clinical development programs. Additional information is included in
the Company’s press release dated November 13, 2006, which is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
c. Exhibits
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
|
|
|
99.1
|
|
Press Release dated November 13, 2006. |